Longer PSA Monitoring in Patients With Persistent PSA May Reduce Overtreatment

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 27, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, March 27, 2025 -- Assessment of prostate-specific antigen (PSA) level for three months after radical prostatectomy (RP) for prostate cancer may minimize overtreatment, according to a study published online March 13 in JAMA Oncology.

Derya Tilki, M.D., from University Hospital Hamburg Eppendorf in Germany, and colleagues examined the time necessary to accurately document a persistent PSA level after RP in a cohort study. The study included patients with T1N0M0 to T3N0M0 prostate cancer treated with RP between 1992 and 2020 at two academic centers. The discovery cohort included 30,461 patients, and the validation cohort included 12,837 patients.

The researchers found that for patients with persistent versus undetectable PSA, a pre-RP PSA level >20 ng/mL versus ≤20 ng/mL was significantly associated with reduced all-cause mortality (ACM) risk and prostate cancer-specific mortality (PCSM) risk (adjusted hazard ratios, 0.69 and 0.41, respectively). These findings persisted after adjustment for prostate volume and were confirmed in the validation cohort for PCSM risk. In patients with a pre-RP PSA >20 ng/mL versus ≤20 ng/mL, there was more frequent and a shorter median time to post-RP radiation therapy plus androgen deprivation therapy (ADT) or ADT use (54.7 percent at a median of 2.68 months versus 34.8 percent at a median of 3.30 months). These treatment times were shorter than those to an undetectable PSA in observed patients (median, 2.96 versus 3.37 months). There was an association seen for increasing persistent PSA level with increased ACM and PSCM risks (adjusted hazard ratios, 1.14 and 1.27, respectively).

"The clinical significance of these findings is that they highlight the need to monitor PSA after RP for longer than the commonly practiced 1.5-month to 2.0-month interval before concluding a persistent PSA exists and initiating post-RP therapy to minimize the risk of overtreatment," the authors write.

One author disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-28 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords